Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DMAC · against 472 other Healthcare companies of similar size
Ranked #306 of 473 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score168 peers with a valuation score of 0–9, including DMAC · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | DMAC | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 459 reported | -7.2% | 0.5% | 27% | 30% | |
| EBITDA yieldHigher is better · 478 reported | -7.9% | 3.5% | 21% | 50% | |
| Free cash flow yieldHigher is better · 204 reported | -5.8% | -5.6% | 49% | 20% | |
| Book yieldHigher is better · 469 reported | 7.1% | 47.5% | 8% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 306 | 475M USD | 8 | 22 | |
| 306 | 365M USD | 8 | 41 | |
| 306 | 357M USD | 8 | 32 | |
| 306 | 635M USD | 8 | 39 | |
| 306 | 539M USD | 8 | 33 | |
| 306 | 647M USD | 8 | 40 | |
| 306 | 399M USD | 8 | 32 | |
| 306 | 4.6B SEK (≈$462M) | 8 | 37 | |
| 306 | 301M USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score